8-K current report · filed Oct 21, 2026

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) 8-K Current Report: October 21, 2026

Item EX-99.1Item 2.02IART overview

Short answer

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K current report with the SEC on October 21, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1.

INTEGRA LIFESCIENCES HOLDINGS CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1
  • Press release includes organic revenue and adjusted EPS guidance, but GAAP guidance unavailable due to unpredictable expenses and foreign exchange
  • Non-GAAP metrics exclude restructuring, acquisition, regulatory, flood recovery, amortization, impairment and related tax effects
  • Impairment adjustments reflect goodwill risk from tariffs, quality issues, operational problems and supply disruptions
  • Investors should compare reported GAAP results with reconciled organic revenue, adjusted profitability and net debt measures in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $411.2M, up 2.3%, despite approximately $7M Cincinnati flood disruption
  • Adjusted EPS $0.59 versus $0.54, while adjusted gross margin fell to 61.1% from 62.9%
  • Specialty Surgery organic growth 4.2%, offset by Tissue Reconstruction organic decline of 2.2%
  • Operating cash flow $96.0M, net debt $1.5B, leverage 3.8x, supporting continued deleveraging
  • $2.1B refinancing extends maturities, but interest rate expected near high end of 100 to 200 basis-point increase range

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other INTEGRA LIFESCIENCES HOLDINGS CORP 8-K filings

Get the next IART 8-K as it lands

Follow IART for push alerts, or ask the research agent what this filing means.